PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
9.36%
Revenue growth at 75-90% of MRVL's 10.96%. Bill Ackman would push for innovation or market expansion to catch up.
15.92%
Gross profit growth above 1.5x MRVL's 10.31%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
75.90%
Positive EBIT growth while MRVL is negative. John Neff might see a substantial edge in operational management.
75.90%
Positive operating income growth while MRVL is negative. John Neff might view this as a competitive edge in operations.
14.77%
Positive net income growth while MRVL is negative. John Neff might see a big relative performance advantage.
-15.38%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-16.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
50.74%
Slight or no buybacks while MRVL is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
51.98%
Slight or no buyback while MRVL is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-35.45%
Dividend reduction while MRVL stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
109.22%
OCF growth above 1.5x MRVL's 41.93%. David Dodd would confirm a clear edge in underlying cash generation.
186.64%
FCF growth above 1.5x MRVL's 102.55%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-48.19%
Negative 10Y revenue/share CAGR while MRVL stands at 82.85%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
21.71%
5Y revenue/share CAGR under 50% of MRVL's 82.85%. Michael Burry would suspect a significant competitive gap or product weakness.
-38.73%
Negative 3Y CAGR while MRVL stands at 82.85%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
36.94%
10Y OCF/share CAGR under 50% of MRVL's 317.63%. Michael Burry would worry about a persistent underperformance in cash creation.
120.38%
Below 50% of MRVL's 317.63%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
8.97%
3Y OCF/share CAGR under 50% of MRVL's 317.63%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
71.28%
Net income/share CAGR at 75-90% of MRVL's 94.38%. Bill Ackman would press for strategic moves to boost long-term earnings.
137.70%
5Y net income/share CAGR 1.25-1.5x MRVL's 94.38%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
-45.79%
Negative 3Y CAGR while MRVL is 94.38%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
127.57%
Positive growth while MRVL is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
59.18%
Positive 5Y equity/share CAGR while MRVL is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-36.96%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
-5.96%
Cut dividends over 10 years while MRVL stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-4.47%
Negative 5Y dividend/share CAGR while MRVL stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-34.92%
Negative near-term dividend growth while MRVL invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-4.66%
Firm’s AR is declining while MRVL shows 19.44%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-1.11%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
2.81%
Positive asset growth while MRVL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-31.13%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-0.48%
We’re deleveraging while MRVL stands at 33.63%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-4.27%
Our R&D shrinks while MRVL invests at 10.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.60%
We cut SG&A while MRVL invests at 3.38%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.